Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)

Escient Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Atopic Dermatitis

Treatments: Drug: Placebo; Drug: Oral EP262

Study type: Interventional

Funder types: Industry

Identifiers

NCT06144424

EP-262-202

Details and patient eligibility

About

This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis

Enrollment: 32 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinically confirmed diagnosis of active atopic dermatitis for at least 1 year
• BSA of 3% to 20% and a vIGA-AD score of ≥3

Exclusion criteria

• Other active skin diseases associated with chronic pruritus
• Clinically infected atopic dermatitis that requires antibiotic therapy
• Use of specific treatments for atopic dermatitis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

32 participants in 2 patient groups, including a placebo group

EP262 150 mg

Experimental group

Treatment:

Drug: Oral EP262

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo